Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parmax PharmaBOM:540359 +0.99%42 PS Ratio is 2.69 as of Aug. 31, 2026, which is 259% above its 10-year median of 0.75. GuruFocus rates BOM:540359 with a GF Score™ of 42/100 and a GF Value™ of ₹40.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 952 Drug Manufacturers companies, Parmax Pharma ranks worse than 54.1% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Parmax Pharma's share price is ₹132.45.
Parmax Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹49.17. Hence, Parmax Pharma's PS Ratio for today is 2.69.
Warning Sign:
Parmax Pharma Ltd stock PS Ratio (=2.67) is close to 10-year high of 2.67.
The historical rank and industry rank for Parmax Pharma's PS Ratio or its related term are showing as below:
BOM:540359'
s PS Ratio Range Over the Past 10 Years
Min: 0.29 Med: 0.75 Max: 2.67
Current: 2.67
During the past 13 years, Parmax Pharma's highest PS Ratio was 2.67. The lowest was 0.29. And the median was 0.75.
BOM:540359's PS Ratio is ranked worse than 54.1% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.375
vs BOM:540359: 2.67
Parmax Pharma Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Parmax Pharma was 21.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -7.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -7.90% per year.
During the past 13 years, Parmax Pharma's highest 3-Year average Revenue per Share Growth Rate was 30.10% per year. The lowest was -25.00% per year. And the median was 3.55% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Parmax Pharma PS Ratio Related Terms
Parmax Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Parmax Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parmax Pharma PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Parmax Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Parmax Pharma's Share Price of today is ₹132.45. Parmax Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹49.17.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Parmax Pharma (BOM:540359) has a PS Ratio of 2.69 as of Aug. 31, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Parmax Pharma and its competitors. This is 259% above median its historical median of 0.75. Over the past decade, Parmax Pharma's PS Ratio has ranged from 0.29 to 2.67. According to the industry distribution chart, Parmax Pharma ranks #515 out of 952 companies in the Drug Manufacturers industry, placing it in the top 54.1%.
Is Parmax Pharma's PS Ratio too high?
Parmax Pharma's current PS Ratio of 2.69 is 259% above median its 10-year median of 0.75. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 2.67. The Drug Manufacturers industry median PS Ratio is 2.38. Parmax Pharma's value of 2.69 is 13.3% above this industry median. Based on the distribution chart, Parmax Pharma ranks #515 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Parmax Pharma has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Parmax Pharma ranks #515 out of 952 companies for PS Ratio. This places Parmax Pharma in the lower half of its industry. The industry median PS Ratio is 2.38. Parmax Pharma's value of 2.69 is 13.3% above this benchmark. Historically, Parmax Pharma's own PS Ratio has ranged from 0.29 to 2.67 over the past decade. While the company's 10-year median is 0.75 vs. the industry median of 2.38, Parmax Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.38, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parmax Pharma's current PS Ratio of 2.69 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Parmax Pharma and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parmax Pharma's current PS Ratio is 2.69, which is 259% above median its own 10-year median of 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹40.79, compared to a current price of ₹132.45 — trading 224.7% above its estimated fair value. The current PS Ratio is 2.69, which is 259% above median its 10-year median of 0.75 and 13.3% above the Drug Manufacturers industry median of 2.38. Parmax Pharma's overall GF Score™ is 42/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current PS Ratio is 2.69 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parmax Pharma (BOM:540359) Overvalued in 2026?
Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued.
The current stock price of ₹132.45 is trading 224.7% above its estimated GF Value™ of ₹40.79.
GuruFocus considers Parmax Pharma to be Significantly Overvalued.
Key valuation signals for BOM:540359:
PS Ratio: 2.69 (259% above median its 10-year median of 0.75)
GF Value™: ₹40.79 vs. price of ₹132.45 (224.7% above fair value)
Industry Position: 13.3% above the Drug Manufacturers median (#515 of 952)
No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540359 has been successfully added to your 
